<DOC>
	<DOC>NCT00483899</DOC>
	<brief_summary>This study was designed to look at safety aspects and effects of repeat inhaled doses of GW870086X in mild asthmatics to develop this drug for its use in asthma and chronic obstructive pulmonary disease (COPD)</brief_summary>
	<brief_title>Examine the Effect of Repeat Inhaled Doses of GW870086X on Lung Function in Mild Asthmatic Male Subjects</brief_title>
	<detailed_description />
	<criteria>Inclusion criteria: Male subjects aged 1855 Documented history of bronchial asthma diagnosed at least 6 months ago. Only being treated with shortacting beta2agonist therapy e.g. Ventolin Documented sensitivity to adenosine mono phosphate (AMP) at screening visit Demonstrate repeatable and reproducable response to inhaled AMP at the runin visit Exclusion criteria: Any significant illness or disease History of life threatening asthma History of respiratory tract infection Subjects who take medication for their asthma, or other conditions, not compatible with this study. Smoker Subjects who are oversensitive to corticosteroids History of drug or alcohol abuse Donated blood within last 3 months Been involved in another clinical trial during the last 3 months Subjects who work night shifts Subjects who are undergoing desensitisation therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>GW870086X Asthma Crossover repeat dose inhaled</keyword>
</DOC>